Review article · 2026 · Open access
Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy
Frontiers in Pharmacology, 17, 1936688 · Published 21 September 2026 · DOI 10.3389/fphar.2026.1936688
In brief
“Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy” is a 2026 review article by Hari Krishnareddy Rachamala and 2 co-authors, published in Frontiers in Pharmacology. OpenAlex counts 0 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Pharmacology.
- Citations
- 0
- References
- 114
- Authors
- 3
Abstract
Cancer immunotherapy is a transformative technology allowing for the elimination of malignant cells through immune system stimulation; however, the large-scale clinical application of adoptive cellular therapy technologies is limited due to difficulties in ex vivo immune cell engineering, high costs, and complicated manufacturing process. Recently, in vivo immune cell engineering was discovered as an emerging approach that allows for the genetic reprogramming of immune cells in patients, thus circumventing many problems inherent to traditional cellular therapy technologies. Breakthroughs in targeted drug delivery systems such as cell-penetrating peptides, antibody- and receptor-mediated delivery approaches, lipid nanoparticles (LNPs), polymeric drug carriers, and biomimetic delivery systems allow for the more effective selective delivery of messenger RNA (mRNA), clustered regularly interspaced short palindromic repeats (CRISPR)/Cas gene editing systems, proteins, and other types of cargo to the target immune cells. In vivo immune cell engineering allows for the efficient generation of chimeric antigen receptor T-cells (CAR-T), CAR- natural killer (NK) cells, engineered macrophages, dendritic cells, and other immune cell types; moreover, transient and permanent immune reprogramming is achievable via vivo technologies. The present review discusses the biological barriers limiting immune cell-targeted delivery, including biodistribution, cellular uptake, intracellular transport, and endosomal escape of delivered drugs, and reviews the latest advancements in targeted delivery technologies addressing these obstacles. We also address the latest applications of in vivo immune cell engineering in hematological malignancies and solid tumors, including mRNA therapeutics, CRISPR-based genome editing, and advanced programmable immunotherapy technologies. Furthermore, we discuss unresolved issues related to the specificity of targeting, efficiency of drug delivery, safety of treatment, manufacturing processes, and regulation of in vivo immune engineering technologies and outline future opportunities arising from the integration of nanomedicine, synthetic biology, genome engineering, and artificial intelligence-assisted materials science.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Rachamala, H. K., Atla, S., & Angom, R. S. (2026). Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy. Frontiers in Pharmacology, 17, 1936688. https://doi.org/10.3389/fphar.2026.1936688
MLA 9
Rachamala, Hari Krishnareddy, et al. “Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy.” Frontiers in Pharmacology, vol. 17, 2026, p. 1936688. https://doi.org/10.3389/fphar.2026.1936688.
Chicago
Rachamala, Hari Krishnareddy, Sandeep Atla, and Ramcharan Singh Angom. 2026. “Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy.” Frontiers in Pharmacology 17: 1936688. https://doi.org/10.3389/fphar.2026.1936688.
Harvard
Rachamala, H. K., Atla, S. and Angom, R. S. (2026) ‘Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy’, Frontiers in Pharmacology, 17, p. 1936688. doi:10.3389/fphar.2026.1936688.
IEEE
H. K. Rachamala, S. Atla, and R. S. Angom, “Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy,” Frontiers in Pharmacology, vol. 17, p. 1936688, 2026, doi: 10.3389/fphar.2026.1936688.
BibTeX
@article{rachamala2026targeted,
title = {{Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy}},
author = {Rachamala, Hari Krishnareddy and Atla, Sandeep and Angom, Ramcharan Singh},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
pages = {1936688},
doi = {10.3389/fphar.2026.1936688},
url = {https://doi.org/10.3389/fphar.2026.1936688}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- targeted drug delivery
- cancer immunotherapy
- cell-penetrating peptides
- lipid nanoparticles
- polymeric drug carriers
- mRNA therapeutics
- CRISPR gene editing
- chimeric antigen receptor T cells
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Rachamala, H. K., Atla, S., & Angom, R. S. (2026). Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy. Frontiers in Pharmacology, 17, 1936688. https://doi.org/10.3389/fphar.2026.1936688
How many times has this paper been cited?
0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Pharmacology: sign in and open the PDF from this page.
Who wrote this paper?
Hari Krishnareddy Rachamala, Sandeep Atla, Ramcharan Singh Angom.
What is the DOI of this paper?
10.3389/fphar.2026.1936688, permanently at https://doi.org/10.3389/fphar.2026.1936688. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.